Seeking Alpha

Shares of Chelsea Therapeutics (CHTP +141%) continue to soar higher on earlier reports of...

Shares of Chelsea Therapeutics (CHTP +141%) continue to soar higher on earlier reports of positive FDA feedback and resubmission guidance on its Northera study. Based on the input, Chelsea plans to file a resubmission of the Northera NDA with the DCRP late in Q213. If accepted, the application will be subject to a 6-month review period.
Comments (2)
  • 59Pound
    , contributor
    Comments (9) | Send Message
     
    Excellent to have the vindication after an up-and-down ride for months. Hope the optimism does not evaporate too soon . . .
    20 Feb 2013, 03:03 PM Reply Like
  • Jay Mooney
    , contributor
    Comments (25) | Send Message
     
    I checked the Calendar - its not April 1
    20 Feb 2013, 03:12 PM Reply Like
DJIA (DIA) S&P 500 (SPY)